Is NCT07683754 recruiting in El Paso, TX?

Yes, NCT07683754 is currently recruiting participants at its El Paso, TX location. This advanced breast cancer clinical trial is actively enrolling qualified participants.

How do I join the advanced breast cancer clinical trial in El Paso?

To join this clinical trial in El Paso, complete the eligibility form on this page. A study coordinator will contact you to discuss next steps and determine if you qualify.

Is participation in this El Paso clinical trial free?

Yes, all study-related care is provided at no cost to qualified participants. Many studies also offer compensation for time and travel expenses.

Advanced Breast Cancer Clinical Trial in El Paso, TX

About This Advanced Breast Cancer Study in El Paso

This study will evaluate a structured sequential treatment strategy starting with T-DXd + pertuzumab upfront therapy, followed by an optimized maintenance therapy with dual HER2+blockade + CDK4/6i + ET and the opportunity to retreat with T-DXd once patients progress under maintenance aimed to maximizing disease control, optimizing tolerability, and preserving T-DXd as a future therapeutic option, while ensuring participant safety and regulatory compliance in participants with HER2+/HR+ advanced/metastatic breast cancer.

Sponsor: Daiichi Sankyo

Who Can Participate

Inclusion Criteria

for Upfront Treatment Phase

Sign and date the Main Trial informed consent form (ICF), prior to the start of any trial-specific procedures.

Participant must be ≥18 years of age at the time the ICF is signed.

Have pathologically documented breast cancer that:

Is locally advanced and unresectable or metastatic (participants who can be treated with curative intent are not eligible).

Participant must have histologically confirmed HER2+ and HR+ (ER+ and/or PR+), mBC. ER, PR, and HER2 measurements should be locally performed according to institutional guidelines.

Is documented by local testing as HR-positive (either ER and/or PgR positive \[ER or PgR ≥1%\]) per ASCO/CAP guidelines in the metastatic setting or from the primary tumor with the latest sample available.

Has not received prior chemotherapy or HER2-targeted therapy for mBC. Participant who has received chemotherapy or HER2-targeted therapy or radiotherapy or surgery in the neoadjuvant or adjuvant setting are eligible, with a DFI of \>6 months (\>183 days) from completion of systemic chemotherapy or any HER2-targeted therapy (antibody, TKI or T-DM1) to diagnosis of advanced or metastatic disease.

ECOG PS of 0 or 1 assessed no more than 3 days prior to initiation of trial intervention.

Has at least 1 lesion, not previously irradiated, that can be measured accurately at baseline as ≥10 mm in the longest diameter (except lymph nodes, which must have short axis ≥15 mm) with CT or MRI, which is suitable for accurate repeated measurements, or nonmeasurable, bone-only disease that can be assessed by CT, MRI, or X-ray.

Participant with brain metastases are allowed if participant is asymptomatic and does not require immediate local intervention. Additional Key Criteria to Transition into the Maintenance Treatment Phase 1\. Participant transitioning into the Maintenance Treatment Phase must meet the following inclusion criteria for Maintenance Treatment:

Participant is without evidence of disease progression under T-DXd + pertuzumab treatment by local assessment according to RECIST v1.1 (ie, CR, PR, or SD), and

Participant is willing to switch therapy, and

Participant completed at least 8 cycles of T-DXd + pertuzumab and achieved cCR (confirmation of CR should be obtained during the next protocol defined scheduled tumor assessment.), or

Participant completed 18 cycles (in total) of T-DXd and achieved a SD or PR, and the last 2 scans showed no further tumor shrinkage (defined as 2 subsequent scans at least 6 weeks apart) or has an unconfirmed CR. Additional Key Criteria for T-DXd Retreatment Phase

Has received at least 1 dose of Maintenance Treatment.

Has documented disease progression per RECIST v1.1 per investigator assessment during Maintenance Treatment.

Participant who experienced ILD Grade 1 during the Maintenance Treatment Phase, must have fully resolved before starting T-DXd during the Retreatment Phase. Key

Exclusion Criteria

for Upfront Treatment Phase

Has prior therapy with any CDK inhibitor.

Previous T-DXd therapy for early BC with an EFS or disease-free interval of \< 12 months from completion of T-DXd therapy in the neoadjuvant or post-neoadjuvant setting. Key Exclusion Criteria for Maintenance Treatment Phase

Is receiving concurrent therapy with other trial interventions (except pertuzumab which is part of Upfront Treatment and Maintenance Treatment).

Has prior therapy with any CDK inhibitor.

Has any unresolved SAE related to prior T-DXd + pertuzumab treatment from the Upfront Treatment Phase, defined as an event that has not resolved to baseline by the time of the eligibility assessment for the Maintenance Treatment Phase.

Has experienced Grade 3 or 4 ILD/pneumonitis during the Upfront Treatment Phase.

Has spinal cord compression or clinically active CNS metastases, defined as untreated or symptomatic, or requiring therapy with corticosteroids or anticonvulsants to control associated symptoms. Key Exclusion Criteria for T-DXd Retreatment Phase

Participant who developed ILD/pneumonitis Grade ≥2 during the Upfront Treatment Phase or Maintenance Treatment Phase.

Participant has any unresolved SAE related to prior Maintenance Treatment Phase therapies defined as an event that has not resolved to baseline by the time of the eligibility assessment for the T-DXd Retreatment Phase.

Participant who developed non-ILD toxicities related to T-DXd in the Upfront Treatment Phase that required T-DXd discontinuation.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in El Paso?

Yes, this clinical trial (NCT07683754) has an active research site in El Paso, TX that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Advanced Breast Cancer Treatment Options in El Paso, TX

If you're searching for advanced breast cancer treatment options in El Paso, TX, this clinical trial (NCT07683754) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our El Paso research site is actively enrolling participants for this phase 3 clinical trial. You'll receive care from experienced advanced breast cancer specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all advanced breast cancer clinical trials near you to find additional studies recruiting in your area.

Advanced Breast Cancer Clinical Trial in El Paso, TX

Expert Care in El Paso

IRB Approved

No-Cost Care

Apply for This El Paso Location

Why Participate?

Simple Process